Arcoma

Arcoma EV/EBITDA

The EV/EBITDA (Enterprise Value to EBITDA) of Arcoma (ARCOMA.ST) as of Oct 23, 2026 is 8.47. In the previous year, EV/EBITDA (Enterprise Value to EBITDA) was 4.48 — a change of 88.93% (higher).

EV/EBITDA

8.47

YoY

88.93%

Last updated:

EV/EBITDA (Enterprise Value to EBITDA) of Arcoma is 2025 8.47 . EV/EBITDA (Enterprise Value to EBITDA) of Arcoma was 2024 4.48 . It decreases by 88.93% higher compared to the previous year.

The Arcoma EV/EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/EBITDA
Date
EV/EBITDA
Jan 1, 2018
30.38 SEK
Jan 1, 2019
9.68 SEK
Jan 1, 2020
27.58 SEK
Jan 1, 2021
-35.72 SEK
Jan 1, 2022
14.81 SEK
Jan 1, 2023
9.43 SEK
Jan 1, 2024
4.48 SEK
Jan 1, 2025
8.47 SEK
The Arcoma EV/EBITDA history
YEAREV/EBITDAYoY
8.47+88.93%
4.48-52.50%
9.43-36.32%
14.81-141.47%
-35.72-229.54%
27.58+184.81%
9.68-68.13%
30.38-242.60%
-21.30-25.99%
-28.78-103.61%
796.29+4,572.99%
17.04—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Arcoma Stock analysis

What does Arcoma do? Arcoma AB generates revenue through the sale of its digital radiographic systems, which include complete systems like ceiling suspensions and floor-mounted units, as well as detectors and components such as overhead tube cranes and radiographic tables. The company markets its products under the IMIX brand, through private label distributors, and as original equipment manufacturer (OEM) solutions. Its primary customers are hospitals, clinics, imaging centers, and private practices seeking digital imaging technology with advanced mobile positioning systems. The Precision and Elite mobile imaging table series are key product offerings within its portfolio. The company's business model relies on direct sales of IMIX-branded systems to healthcare facilities, while also supplying components to private label distributors and OEM partners. These channels allow Arcoma to reach a broad range of healthcare providers across different segments. The firm's product range targets facilities requiring flexible, mobile imaging solutions for diagnostic procedures. Arcoma AB's revenue streams are derived from the sale of complete radiographic systems, system components, and mobile imaging tables, all designed for healthcare environments. The IMIX brand represents the company's direct-to-customer offering, while private label and OEM arrangements provide additional distribution pathways. The Precision and Elite series specifically cater to the needs of medical practices requiring mobile diagnostic equipment. Arcoma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Arcoma stock

EV/EBITDA (Enterprise Value to EBITDA) of Arcoma is 8.47 in 2025.

EV/EBITDA (Enterprise Value to EBITDA) of Arcoma changed from 4.48 to 8.47, representing a 88.93% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/EBITDA (Enterprise Value to EBITDA) Arcoma since 2006 – with annual values, charts, and detailed analysis.

The EV/EBITDA ratio is a widely used valuation metric that compares a company's enterprise value to its EBITDA. It normalizes for differences in capital structure, taxation, and depreciation policies.

To evaluate EV/EBITDA (Enterprise Value to EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBITDA (Enterprise Value to EBITDA).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBITDA (Enterprise Value to EBITDA)'s Arcoma with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Arcoma

All Key Metrics — Arcoma